Key result
In vitro assembly of virus-like particles from purified monomers avoids encapsidation of host-derived components and enables loading with added cargoes compared to in vivo assembly.
Why the study?
In vitro VLP assembly from purified monomers is advantageous over in vivo assembly by avoiding host-derived components and enabling cargo loading, motivating an overview of ex cella production methods and applications.
This review provides an overview of ex cella virus-like particle (VLP) production methods, factors impacting in vitro assembly, and their applications in vaccines and therapeutic delivery.
In vitro VLP assembly enables controlled cargo loading without host contaminants; leaves open scalability and clinical translation for vaccines.
Virus-like particles (VLPs) are increasingly used for vaccine development and drug delivery. Assembly of VLPs from purified monomers in a chemically defined reaction is advantageous compared to in vivo assembly, because it avoids encapsidation of host-derived components and enables loading with added cargoes. This review provides an overview of ex cella VLP production methods focusing on capsid protein production, factors that impact the in vitro assembly, and approaches to characterize in vitro VLPs. The uses of in vitro produced VLPs as vaccines and for therapeutic delivery are also reported.
No takes yet. Share an insight, caveat, or question.
Le et al. (2021) reported a review. In vitro assembly of virus-like particles (VLPs) vs. In vivo assembly was evaluated. In vitro assembly of virus-like particles from purified monomers avoids encapsidation of host-derived components and enables loading with added cargoes compared to in vivo assembly.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: